このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Eye Tracking for Early Identification of Post-ICU Cognitive Impairment

2026年6月24日 更新者:Shanghai Zhongshan Hospital

Early Identification of Post-ICU Cognitive Impairment Using Eye-Tracking Technology: A Prospective Observational Study

Some patients may have problems with memory, attention, thinking speed, or other cognitive functions after leaving the intensive care unit (ICU). This is called post-ICU cognitive impairment. Early recognition of this problem may help clinicians provide follow-up care and support more promptly.

This study will explore whether eye-tracking technology can help identify cognitive impairment in patients soon after ICU discharge. Eye tracking is a non-invasive test that records eye movements while a person looks at images or completes simple visual tasks on a screen. The test does not involve any treatment or change in usual medical care.

Participants will be adult patients who have been transferred from the ICU to a general ward. Within 7 days after ICU discharge, participants will complete a cognitive assessment and an eye-tracking test. The study team will also collect relevant clinical information from medical records. Patients will be grouped according to whether they have post-ICU cognitive impairment based on cognitive assessment and clinical judgment.

The main purpose of this study is to assess whether information obtained from eye-tracking tests can help clinicians identify possible post-ICU cognitive impairment at an early stage, when used together with standard cognitive assessment. The study will also compare eye movement patterns between the two groups and explore whether eye-tracking measures add useful information beyond standard cognitive assessment.

調査の概要

状態

まだ募集していません

詳細な説明

Post-intensive care syndrome-cognitive impairment (PICS-CI) is a common problem among patients after discharge from the intensive care unit (ICU). It may involve difficulties with memory, attention, executive function, information processing speed, visuospatial ability, or language. These problems may affect long-term recovery, quality of life, treatment adherence, and social participation. Early identification of possible cognitive impairment after ICU discharge is therefore important for follow-up care and rehabilitation planning.

Current assessment of post-ICU cognitive impairment mainly relies on cognitive screening scales and clinical judgment. Although these methods are widely used, they may be influenced by a patient's level of cooperation, education, emotional state, fatigue, and subjective responses. Eye-tracking technology provides objective and quantitative information about eye movement behavior during visual and cognitive tasks. Because eye movements are closely related to attention, inhibitory control, visual processing, and other cognitive processes, eye-tracking-derived parameters may provide additional information to support early cognitive screening after ICU discharge.

This is a prospective, single-center, observational study conducted at Zhongshan Hospital, Fudan University. The study will enroll patients who have been transferred from the ICU to a general ward after ICU treatment. No treatment, medication, device intervention, or change in usual clinical care will be assigned by the study. All study procedures will be performed on the basis of routine care and are intended for research assessment only.

Within 7 days after ICU discharge, participants will complete a standardized cognitive assessment and an eye-tracking test. Cognitive status will be assessed using the Montreal Cognitive Assessment (MoCA), with education-based score correction, together with clinical judgment under the DSM-5 framework for neurocognitive disorders. Based on this assessment, participants will be classified as having post-ICU cognitive impairment or not having post-ICU cognitive impairment.

During the eye-tracking test, participants will complete predefined visual cognitive tasks in a standardized testing environment. Eye movement data will be recorded using eye-tracking equipment and processed using Tobii Pro Lab software according to predefined areas of interest, time windows, and saccade identification rules. Eye-tracking-derived parameters may include saccade latency, saccade accuracy, saccade error rate, mean saccade amplitude, mean saccade velocity, mean saccade duration, fixation time, and uncorrected error rate. These parameters will be used to describe eye movement behavior related to response initiation, attention orientation, inhibitory control, spatial localization, eye movement execution, and visual processing.

The study team will also collect demographic and clinical information from medical records, including age, sex, education level, ICU-related clinical characteristics, disease severity, ICU length of stay, mechanical ventilation, sedative and analgesic exposure, and other clinically relevant factors. These data will be used to describe the study population and to adjust for potential confounding factors in the analysis.

The main objective of this study is to evaluate whether eye-tracking-derived parameters, alone or in combination, can support the early identification of post-ICU cognitive impairment as an auxiliary tool to standard cognitive assessment. The study will compare eye movement characteristics between patients with and without post-ICU cognitive impairment and examine the association between eye-tracking-derived parameters and cognitive status. The diagnostic performance of selected eye-tracking parameters or parameter combinations will be evaluated using receiver operating characteristic curve analysis. Exploratory models may also assess whether adding eye-tracking-derived parameters to clinical and cognitive assessment information improves identification performance.

Eye tracking is non-invasive and does not involve radiation, medication, or invasive procedures. Some participants may experience temporary eye fatigue, visual discomfort, dizziness, nausea, or other mild discomfort while looking at the screen or completing the visual tasks. The research team will monitor participants during testing and may pause or stop the test if needed. All collected data will be de-identified and managed according to the study data management plan to protect participant privacy and data security.

研究の種類

観察的

入学 (推定)

73

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Ai rong Zhu, Bachelor's Degree
  • 電話番号:+86 15160007359
  • メール:2471015405@qq.com

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

The study population will consist of patients who have been successfully transferred from the intensive care unit (ICU) to a general ward after ICU treatment at Zhongshan Hospital, Fudan University. Eligible participants will have stayed in the ICU for at least 24 hours, be conscious, and be able to complete cognitive assessment and eye-tracking tests. Participants will undergo study assessments within 7 days after ICU discharge. No intervention will be assigned by the study.

説明

Inclusion Criteria:

  • Successfully transferred from the ICU to a general ward after ICU treatment.
  • ICU length of stay of at least 24 hours.
  • Conscious and able to cooperate with cognitive assessment and eye-tracking tests.
  • Willing to participate in the study and able to provide written informed consent.

Exclusion Criteria:

  • Diagnosed with cognitive impairment before ICU admission, such as Alzheimer's disease, based on medical history or previous medical records.
  • Previous diagnosis of mental illness or intellectual developmental disorder.
  • Severe visual, hearing, or eye disease that prevents completion of cognitive assessment or eye-tracking tasks.
  • Severe neurological disease that may affect cognitive function, such as stroke, traumatic brain injury, or intracranial infection.
  • Unable to understand or complete the cognitive assessment or eye-tracking tasks due to severe fatigue, marked inattention, communication disorder, or other reasons as assessed by the research staff.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Post-ICU Cognitive Impairment Group
Participants diagnosed with post-ICU cognitive impairment based on DSM-5 criteria, clinical assessment, and corrected MoCA score.
Non-Post-ICU Cognitive Impairment Group
Participants without post-ICU cognitive impairment based on DSM-5 criteria, clinical assessment, and corrected MoCA score.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Auxiliary Identification Performance of Eye-Tracking-Derived Parameters for Post-ICU Cognitive Impairment
時間枠:Within 7 days after ICU discharge
The area under the receiver operating characteristic curve (AUC) will be used to evaluate how well selected eye-tracking-derived parameters, alone or in combination, support the identification of post-ICU cognitive impairment. Post-ICU cognitive impairment will be determined using DSM-5 neurocognitive disorder criteria together with clinical assessment and education-corrected Montreal Cognitive Assessment (MoCA) score.
Within 7 days after ICU discharge

二次結果の測定

結果測定
メジャーの説明
時間枠
Occurrence of Post-ICU Cognitive Impairment
時間枠:Within 7 days after ICU discharge
The proportion of enrolled participants classified as having post-ICU cognitive impairment will be summarized. Post-ICU cognitive impairment will be determined using DSM-5 neurocognitive disorder criteria together with clinical assessment and education-corrected MoCA score.
Within 7 days after ICU discharge
Differences in Eye-Tracking-Derived Parameters Between Cognitive Status Groups
時間枠:Within 7 days after ICU discharge
Eye-tracking-derived parameters will be compared between participants with and without post-ICU cognitive impairment. Parameters may include saccade latency, saccade accuracy, saccade error rate, mean saccade amplitude, mean saccade velocity, mean saccade duration, fixation time, and uncorrected error rate.
Within 7 days after ICU discharge

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月1日

一次修了 (推定)

2027年1月1日

研究の完了 (推定)

2027年5月1日

試験登録日

最初に提出

2026年6月24日

QC基準を満たした最初の提出物

2026年6月24日

最初の投稿 (実際)

2026年6月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月30日

QC基準を満たした最後の更新が送信されました

2026年6月24日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する